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The diagnosis and management of patients with stable ischaemic heart disease (SIHD) is challenging, costly, imprecise, and in need of improvement. In patients without established coronary artery disease (CAD) who undergo functional testing, <60% of those referred for invasive coronary angiography (ICA) are typically found to have significant CAD (>50% stenosis). 1 As compared with the most commonly performed functional tests, coronary computed tomographic angiography (CTA) has higher sensitivity for identifying angiographically significant CAD, is at least as effective in comparative outcomes studies, and is associated with higher use of preventive medications (e.g. statins), lower rates of incident myocardial infarctions (MI), and lower rates or normal ICA. [2] [3] [4] As a result, some recent international guidelines have broadly endorsed coronary CTA as the preferred initial test for symptomatic patients without established CAD. 5 However, as an anatomical test, CTA is associated with a small but significant increase in the proportion of patients referred to ICA as compared with functional testing. 6 While the optimal proportion and selection of patients to send for ICA following non-invasive testing is unknown, these results remind us that the 'occulostenotic reflex' is probably alive and well. In light of the unclear effectiveness of coronary revascularization over medical therapy in SIHD, especially in patients without high-risk CAD (e.g. left main, three-vessel CAD) or medically refractory angina, and the costs and invasive nature of ICA, strategies to improve the selection of patients for invasive study are welcomed. Measurement of the physiological significance of CAD using fractional flow reserve (FFR) during ICA is preferred over angiography to guide revascularization in stable patients. As such, there has been marked enthusiasm regarding the development of CT-derived estimates of FFR using static coronary CTA data sets. Utilizing complex mathematical models based on computational fluid dynamics and, more recently, machine learning, FFR can be estimated from CTA (FFRct) based on coronary geometry, subtended myocardial mass, and the estimation of myocardial blood flow at rest and at simulated hyperaemia. The majority of studies to date, and almost all of the clinical experience, have utilized FFRct technology developed by HeartFlow (Redwood City, CA, USA), where CTA data sets are transferred to a cloud server and analysed using a super-computer, with the FFRct report provided to users in a few hours. The current published US Medicare fee for the performance of HeartFlow's FFRct is US$1450.50.
Studies to date using HeartFlow FFRct have almost exclusively been sponsored by or performed by investigators supported by HeartFlow. We have learned that FFRct improves the specificity and the overall diagnostic accuracy of coronary CTA for identifying lesions with abnormal invasive FFR, as compared with stenosis alone. As expected, FFRct is highly dependent on image quality. In the NXT trial, 13% of studies were rejected due to inadequate image quality. 7 Importantly, the limits of agreement between FFRct and invasive FFR appear to be relatively wide, at least when FFRct values are between 0.7 and 0.9 (not clearly normal or abnormal), suggesting that there may be a larger clinical 'grey zone' for FFRct as compared with invasive FFR. 8 Unlike invasive FFR, the most clinically effective and safest 'cut-off point' for FFRct on which to base management decisions was never prospectively derived, but has been extrapolated from invasive FFR (0.75-0.80). There also remains clinical uncertainty about the diagnostic accuracy of abnormal FFRct values seen only at the very smallest, distal coronary vessel segments. Finally, the majority of studies outside of the clinical trial setting have been from single centres, with no studies performed assessing measured or direct costs or cost-effectiveness.
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Clinical implications and ongoing questions
The current results represent a much-needed, real-world assessment of this exciting, disruptive technology. The finding that utilization of medical therapy was increased, with fewer patients referred to ICA, is a welcomed sign, especially among SIHD patients where the longterm benefit of coronary revascularization is uncertain. Additionally, studies to date have not fully evaluated the prognostic value of FFRct for clinical outcomes. While the ascertainment of clinical outcomes was limited to 90 days, FFRct appeared to stratify short-term 'hard' adverse events accurately. Longer term follow-up of this cohort is of significant interest. There are, of course, several important limitations regarding the current study, and the broader evidence base for FFRct, that deserve discussion.
Patients: low anginal severity, many without symptoms, and unclear baseline medications
In the absence of significant left main, proximal left anterior descending (LAD) or multivessel CAD, appropriate use criteria typically restrict coronary revascularization to patients with medically refractory, lifestyle-limiting angina. In the current analysis, baseline medications were not reported and medications and symptoms were not considered in core lab recommendations. Hence, the primary outcome was a simulation exercise that is not reflective of guidelines or routine clinical care. Among those with typical angina, 80% had CCS (Canadian Cardiovascular Society) class I-II angina. More perplexing, 24% of subjects were asymptomatic. Adverse plaque features, which have been shown to influence prognosis and probability of an abnormal invasive FFR, were not considered by the current version of FFRct and not reported. 12 
Grey zone and accuracy concerns
In the current study, 253 and 515 patients, respectively, had an FFRct < _0.80 despite having a normal (no plaque) or minimal stenosis (0-30%) on coronary CTA. While no test is perfect, this raises concerns about the accuracy of FFRct, particularly when used in a binary fashion to guide decision-making.
Risk of bias: endpoints and funding
It deserves mentioning that investigators, both core lab readers and site investigators, were well aware of the aims of the study, with many receiving support from the study sponsor. The potential for residual confounding in the form of unintentional information bias on post-CTA management recommendations by both core lab readers and sites remains a concern. Furthermore, we do not know how patients would have been managed without FFRct due to the open label nature of the study. Similarly, we are not provided with data on the percentage of patients who underwent CTA at sites and were not enrolled. As such, it is possible that those with poor image quality may have been excluded from enrolment, as only 3% of studies were rejected for analysis due to image quality, a figure that is much lower than seen in all prospective clinical trials using FFRct. Ultimately, this important technology should be rigorously tested in an independent manner.
Cost and competition
Given the relatively low cost of coronary CTA, performance of FFRct increases the cost of the overall CT study by >4-fold. If unnecessary ICA and revascularizations can be avoided, then FFRct may prove to be cost-effective, but independent studies using measured costs are needed. Given the high cost of FFRct, better criteria are needed to select patients most likely to benefit. For example, those with clearly severe, high-risk lesions (e.g. 80-90% proximal LAD) or unequivocally low-risk lesions (distal, branch vessel) can surely be managed using CTA alone.
In conclusion, I believe that FFRct represents an important advance in the field of cardiovascular medicine but one that will continue to be refined (Figure 1) . I am optimistic that by leveraging advances in computational capabilities and machine learning, on-site FFRct may allow accurate assessments to be performed more quickly and in a less costly manner. 13 Ultimately, current users of FFRct should continue to integrate these valuable results with patient symptoms, medications, clinical guidelines, CTA image quality, and lesion location.
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